Biotech Values

[DewDiligence]

How MNTA Executed Against Its 2008 Internal Goals (corrected)

[These are the numbers used by the compensation committee
to determine the 2008 bonuses for MNTA’s executive officers.
Please see the footnotes for additional details.]

 
                                      Weighting    Actual Level     Weighted  
 Corporate Goal                        of Goal    of Achievement   Achievement  
    
 *Addressing FDA’s immunogenicity  
 questions on Lovenox ANDA . . . . . . . 15%           70%           10.5%  
    
 Ongoing review and approval  
 of Lovenox ANDA . . . . . . . . . . . . 10%           70%            7.0%  
    
 ‡Advancement of M356   
 (generic Copaxone) program  . . . . . . 15%          100%           15.0%  
    
 Advancement of glycoprotein  
 (FoB) program . . . . . . . . . . . . . 10%          100%           10.0%  
    
 Advancement of undisclosed  
 research programs . . . . . . . . . . .  5%           70%            3.5%  
    
 †Commencement of phase-2b  
 trial for  M118 . . . . . . . . . . . . 10%            0%            0.0%  
    
 “Financial discipline”  . . . . . . . . 10%          100%           10.0%  
    
 **Completion of financing . . . . . . . 25%          100%           25.0%  
                                        ====                         =====  
 TOTAL                                  100%                         81.0%  
  
  
 *Response to FDA submitted 9/28/06 (#msg-32449872). 
 70% execution reflects the relatively long 10-month 
 turnaround time for the submission. 
  
 ‡Copaxone ANDA submitted to FDA in late 2007 and 
 accepted by FDA for review on 7/11/08 (#msg-30621490). 
  
 †Start of phase-2b has been delayed by the prerequisite  
 for a phase-2a trial in elective PCI (#msg-26809439). 
  
 **$24.1M was raised in Dec 2008 (#msg-34156708).

Source:
http://sec.gov/Archives/edgar/data/1235010/000104746909004743/a2192562zdef14a.htm